I don't think they like me too much, Bobby, but that's okay. Eli Lilly and Novo Nordisk are committing to offer Zepbound and WeGovy at most favored nations rates for American patients. This will slash the cost of WeGovy from $1,350 a month to ultimately $250 a month. $1,350 to $250. Did I do a good job? They don't write about it. You know, they like to not write these things and reduce. (05:01–05:12)
CLAIM
Asserts that the cost of WeGovy will be reduced significantly.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
